Patient Recruitment to Commence in IntelGenx’s Phase 2a Montelukast VersaFilm™ Trial in Mild to Moderate Alzheimer’s Disease
September 25, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient recruitment will commence for the...
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
June 01, 2017 09:05 ET
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...